✦ LIBER ✦

Hemorheological changes in patients undergoing haemodialysis for chronic renal failure and retinal ischaemia

✍ Scribed by Elgohary, M

Book ID: 110035462
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 92 KB
Volume: 18
Category: Article
ISSN: 0950-222X
DOI: 10.1038/sj.eye.6701371

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nail changes in chronic renal failure pa

Nail changes in chronic renal failure patients under haemodialysis

✍ A Salem; S Al Mokadem; E Attwa; S Abd El Raoof; HM Ebrahim; KT Faheem 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 795 KB

Nail disorders in patients with chronic

Nail disorders in patients with chronic renal failure and undergoing haemodialysis treatment: a case–control study

✍ P Dyachenko; A Monselise; A Shustak; M Ziv; D Rozenman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

Bone histological changes occurring afte

Bone histological changes occurring after haemodialysis treatment for chronic renal failure

✍ C. G. Woods; M. C. Bishop; G. D. Nicholson 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 English ⚖ 770 KB

Citalopram pharmacokinetics in patients

Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis

✍ Olav Spigset; Staffan Hägg; Bernd Stegmayr; Rune Dahlqvist 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 91 KB

Serum ghrelin concentrations in patients

Serum ghrelin concentrations in patients with chronic renal failure undergoing dialysis

✍ Pedro Iglesias; Juan J. Díez; María J. Fernández-Reyes; Rosa Codoceo; Pilar Alva 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

Oral pharmacokinetics of pirenzepine in

Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis

✍ T. MacGregor; K. Matzek; J. Keirns; M. Vinocur; A. Chonko 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 215 KB

The pharmacokinetic properties of pirenzepine following administration of a single, 50 mg oral dose were evaluated in three groups of subjects: group I, end stage renal disease requiring maintenance haemodialysis (CLCR 0 to 10 ml.min-1); group II, moderate renal insufficiency (CLCR 10 to 30 ml.min-1